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ABSTRACT
P2X7 is an important ligand-gated ion channel expressed in
multiple immune cell populations. This study aimed to investi-
gate the chemical requirements of triterpenoid glycosides within
a new binding pocket to characterize the structure-activity
relationship. A set of glycosides were screened for positive
modulator activity at human P2X7 using a YO-PRO-1 dye uptake
assay in HEK-293 cells stably expressing the wild-type human
P2X7 variant (HEK-hP2X7 cells). The highest positive modulator
activity was with ginsenoside–compound K (CK), containing
a monosaccharide (glucose) attached at carbon-20. Ginseno-
side-20(S)-Rg3, containing a disaccharide group (glucose-glu-
cose) at carbon-3, displayed positive modulator activity with
a reduced EC50 for ATP and increased maximal response at
humanP2X7. The epimer 20(R)-Rg3was inactive. A similar stereo-
specific pattern was observed for 20(S)-Rh2. Ginsenoside-F1,
highly similar to ginsenoside-CK but containing a single additional
hydroxyl group,was also inactive at P2X7.Computational docking
suggests hydrophobic residues in the pocket are involved in steric
discrimination between triterpenoids, whereas the position and
identity of the carbohydrate group are important for positive
modulator activity at human P2X7. Ginsenosides containing
monosaccharide attachments perform better than di- or trisac-
charide glycosides. Additional modifications to the triterpenoid
scaffold at carbon-6 are not tolerated. Gypenosides from plant
sources other than Panax ginseng (gypenoside XVII, gypenoside
XLIX, stevenleaf) can also act as positive allosteric modulators
of P2X7. We also investigated the effect of positive allosteric
modulators on endogenous P2X7 in THP-1 monocytes and
confirmed our findings in a calcium response assay. A cell
viability assay showed potentiation of ATP-induced cell death
with ginsenoside-CK in THP-1 and HEK-hP2X7 cells.
SIGNIFICANCE STATEMENT
Ginsenosides are active as positive allosteric modulators at
P2X7, and this study determines the chemical features
important for mediating this effect. The position and identity
of the sugar group is important for activity, as is the position
of a number of hydroxyl groups on the triterpenoid scaffold.
Diastereomers of ginsenoside-Rg3 and ginsenoside-Rh2
demonstrate the importance of the location of hydroxyl
groups relative to the hydrophobic face of the predicted
binding pocket.
Introduction
The ligand-gated ion channel P2X7 is important in regulat-
ing immune cell responses during infection and inflammation
(Di Virgilio et al., 2017). In particular, P2X7 is a known
physiologic regulator of the NLRP3–caspase 1 inflammasome
complex and controls the secretion of proinflammatory cyto-
kines such as interleukin-1b and interleukin-18 (Giuliani
et al., 2017). Many studies have demonstrated that activation
of P2X7 in infected macrophages in vitro can promote
microbial killing. Intracellular bacteria and parasites such
asMycobacterium tuberculosis (Fairbairn et al., 2001, Placido
et al., 2006), Toxoplasma gondii (Moreira-Souza et al., 2017),
and Leishmania amazonensis (Chaves et al., 2014) are exam-
ples of pathogens in which P2X7 contributes to microbicidal
mechanisms. In vivo mouse models of infection suggest that
global deficiency in P2X7 can affect pathogen burden and
inflammation (Miller et al., 2015; Chaves et al., 2019). Further-
more, inheritance of loss-of-function variants of human P2X7
have been linked to susceptibility to infections and complica-
tions such as extrapulmonary tuberculosis (Fernando et al.,
2007; Areeshi et al., 2015). Development of a positive allosteric
modulator (PAM) of P2X7may therefore be useful in treatment
of such infections (Stokes et al., 2020). This type of therapy
directed at enhancing host responses would reduce the need for
antibiotics and be beneficial in avoiding development of
antibiotic resistance.
Triterpenoidglycosides fromPanaxginsenghavePAMactivity at
human P2X7with the in vivometabolite ginsenoside–compoundK
(CK) demonstrating the highest activity (Helliwell et al.,
2015). Using a combination of computational docking and
mutagenesis, we previously characterized a novel binding
pocket for ginsenosides within the central vestibule of human
P2X7 (Bidula et al., 2019b). Predicted binding poses identified
twomodes of binding dependent on the carbohydrates attached
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carbohydrate (glucose) moiety that makes multiple contacts
with amino acids Asp318, Leu320 and Ser60. Conversely,
ginsenoside-Rd contains both disaccharide (-glucose-glucose)
and monosaccharide glucose moieties and is predicted to use
the disaccharide moiety for binding to P2X7 (Bidula et al.,
2019b). The presence of carbohydrate moieties is deemed
essential for PAM activity since the aglycone protopanaxadiol
has no activity at P2X7 (Helliwell et al., 2015).
In this study, we explored the chemical structural require-
ments of triterpenoid glycosides with the aim of building
a structure-activity relationship for positive modulators at
P2X7. This revealed critical information about the tolerance of
substitutions at carbon (C)-6 and the preference for glucose as
the attached sugar moiety. This provides important knowl-
edge for the future development of selective PAMs for P2X7.
Materials and Methods
Materials. Ginsenoside-CK (CAS 39262-14-1), ginsenoside-Rb1
(CAS 41753-43-9), ginsenoside-Rd (CAS 52705-93-8), 20(S)-ginseno-
side-Rg3 (CAS 14197-60-5), 20(R)-ginsenoside-Rh2 (CAS 112246-15-
8), protopanaxadiol (PPD) (CAS 30636-90-9), glycyrrhizic acid (CAS
1405-86-3), stevioside (CAS 57817-89-7), daucosterol (CAS 474-58-8),
esculentoside A (CAS 65497-07-6), mogroside V (CAS 88901-36-4),
saikosaponin A (CAS 20736-09-8), and stevenleaf (CAS 80321-63-7)
were from Shanghai Richem International Ltd., China (supplier code
CDCMANSETE). Ginsenoside-CK (CAS 39262-14-1), ginsenoside-F2
(CAS 62025-49-4), ginsenoside-F1 (CAS 53963-43-2), gypenoside
XLIX (CAS 94987-08-3), gypenoside XVII (CAS 80321-69-3), 20(S)-
ginsenoside-Rg3 (CAS 14197-60-5), 20(R)-ginsenoside-Rg3 (CAS
38243-03-7), 20(S)-ginsenoside-Rh2 (CAS 78214-33-2), and 20(R)-
ginsenoside-Rh2 (CAS 112246-15-8) were from ChemFaces (Wuhan
Chemfaces). Scilliroside (CAS 507-60-8,NSC7523), ouabain (CAS 630-
60-4, NSC25485), solanine hydrochloride (CAS 20562-02-1,
NSC35611), and solasonine (CAS 19121-58-5, NSC82149) were
obtained from the National Cancer Institute Developmental Thera-
peutics Program chemical repository. ATP (A7699; Sigma-Aldrich)
was dissolved in distilledwater to 100mMand adjusted to pH 7.4 with
5 M NaOH. Aliquots of ATP were kept frozen at220°C and used once
in experiments. AZ10606120 (CAS 607378-18-7; Tocris Biosciences)
and AZ11645373 (CAS 227088-94-0; Sigma-Aldrich) were dissolved in
DMSO to 10 mM and stored at 220°C. Fura-2 acetoxymethyl ester
(AM) (CAS 108964-32-5; HelloBio) was prepared in DMSO to a con-
centration of 1 mM, aliquoted, and stored at 220°C in amber-colored
Eppendorf vials. Sulfinpyrazone (CAS 57-96-5; Sigma Aldrich) was
dissolved in methanol at a stock concentration of 25 mM and stored at
+4°C.
Cell Culture. HEK-293 cells stably expressing the wild-type
human P2X7 (hP2X7) variant (HEK-hP2X7) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM):F12 (catalog number
11320-074; ThermoFisher Scientific, Life Technologies) containing
10% fetal bovine serum (catalog number 10500-064; Gibco) and
penicillin/streptomycin (ThermoFisher Scientific) as described previ-
ously (Helliwell et al., 2015). HEK-293 cells were passaged twice weekly
using 0.25% trypsin-EDTA (ThermoFisher Scientific). THP-1 human
monocytic cells (a kind gift from Professor Maria O’Connell, University
of East Anglia) were maintained in RPMI 1640 medium (catalog
number 21875-034, Fisher Scientific, Life Technologies) containing
10% fetal bovine serum (Gibco, as before) and penicillin/streptomycin
(ThermoFisher Scientific). Cells were kept in a humidified incubator at
37°C with a constant supply of 5% CO2.
YO-PRO-1 Dye Uptake Screening Assay. ATP-induced dye
uptake experiments were performed as described previously (Bidula
et al., 2019b). Briefly,HEK-hP2X7 cells were plated at 2 104 cells per
well (100 ml per well) in complete medium and left overnight to attach
to poly-D-lysine–coated 96-well plates. YO-PRO-1 iodide was prepared
in a low divalent buffered solution (145 mM, 2 mM KCl, 13 mM
D-glucose, 10 mM HEPES, 0.2 mM CaCl2 pH 7.3) to a final concentra-
tion of 2 mM. Medium was removed from the plate using a manual
multichannel pipette andYO-PRO-1 containing buffer applied towells
(180ml per well). AZ10606120 (10 mM)was prepared in YO-PRO-1 low
divalent buffer and added directly to the cells to block P2X7 by
pretreatment. A Flexstation 3 plate reader (Molecular Devices,
Sunnyvale, CA) was used to record YO-PRO-1 fluorescence in HEK-
hP2X7 for 300 seconds after the addition of ATP (at 10 final
concentration) with/without ginsenoside compounds or vehicle
(DMSO). Plates were allowed to warm up to 37°C for 10 minutes
before initiating the recording. Baseline recordings were made for 40
seconds before compound addition using the Flexstation 3 fluidics
system. YO-PRO-1 fluorescence was measured at 520 nm after
excitation at 490 nm (auto cutoff at 495 nm), and the sample interval
was 3.5 seconds. Flexstation settings were photomultiplier tube
(PMT) medium, six reads per well, pipette height 170, and a rate of
injection of 3. Data were acquired using Softmax Pro version 5.4
(Molecular Devices). To analyze the data, area under the dye uptake
curvewas calculated in SoftmaxPro version 5 using zero baseline data
with a lag time of 50 seconds (50–300 seconds).
Fura-2 Calcium Measurements. THP-1 cells were pelleted by
centrifugation (300g, 5 minute), washed, and resuspended in Hanks’
balanced salt solution buffer containing 2 mM fura-2 AM (HelloBio)
and 250 mM (6)-sulfinpyrazone. Cells were loaded for 1 hour in
a waterbath at 37°C while shielded from light with foil. Loaded cells
were washed once with 5 ml Hanks’ balanced salt solution to remove
excess fura-2 AM dye. THP-1 cells were then resuspended, counted,
and plated at 2  105 cells per well in a standard clear 96-well plate
(NUNC 167008; Thermo Scientific) in low divalent assay buffer
without Mg2+ (145 mM NaCl, 2 mM KCl and 2 mM CaCl2, 13 mM
glucose, 10 mM HEPES, pH 7.3) containing 250 mM (6)-sulfinpyra-
zone. The 10 concentration of agonist (ATP) was prepared in the
same assay buffer. ATP was injected automatically into wells at 30
seconds in a Flexstation 3 microplate reader. Ratiometric data were
acquired using 340 and 380 nm for excitation wavelengths, 520 nm as
the emission wavelength, and six reads per well (PMTmedium). Area
under the curve was calculated using standard zero baseline normal-
ization with a lag time 0–300 seconds using SoftMax Pro version 5.4
software.
Cell Viability Assay. HEK-hP2X7 or THP-1 cells were seeded at
5 103 cells perwell in a volume of 100ml for 24 hours in 96-well plates
(Nunclon Edge plates, catalog number 167425; Thermo Scientific).
Cells were plated in DMEM:F12 medium or RPMI 1640 medium
containing 1% FBS and penicillin/streptomycin for 24 hours in
a humidified incubator at 37°C with a constant supply of 5% CO2.
Edge wells of the plates were filled with autoclaved distilled water to
prevent evaporation of media from wells containing cells. The com-
pounds and ATP were made at 2 final concentration in 1% FBS
DMEM:F12 and 100 ml added to the cells for 24 hours. After
incubation, resazurin sodium salt (CAS 62758-13-8; Sigma Aldrich)
at 0.1 mg/ml in sterile PBS was added to the plate (20 into 200 ml
culturemediumper well). Cells were incubated for a further 2 hours in
a humidified incubator at 37°C with a supply of 5% CO2. A Flexstation
3 microplate reader was used to acquire data. Endpoint fluorescence
data were measured using 570 nm excitation wavelength, 600 nm
emissionwavelength (cutoff at 590 nm), and three reads perwell (PMT
low). Data were analyzed by performing background correction
through subtracting blank medium readings (without cells) from all
samples and then normalizing each sample to medium treated cells
(control treatment, 100%) as percentage of control.
Computational Docking. The homology model of human P2X7
generated previously in (Bidula et al., 2019b) was used for docking
runs using the Schrödinger Maestro suite. Three-dimensional models
of ginsenoside-F1 and ginsenoside-20(S)-Rg3 were generated using
LigPrep software, and the OPLS3 force field was used to generate up
to 32 low-energy conformers for each ligand. Induced-fit docking was












performed using the automated extended sampling protocol, first
performing several initial docking runs in which either side chains
were trimmed or van der Waals potentials were softened according to
their flexibility; then side chains were rebuilt, and those within 5 Å of
the ligand were optimized using Prime software (Jacobson et al.,
2004). Structures within 30 kcal mol21 of the lowest energy structure
were retained. Ligands were then redocked to the new receptor
structure using the Glide SP algorithm (Friesner et al., 2004) and
standard potentials. The receptor grid was centered on the highest
scoring potential binding site using SiteMap (Halgren, 2007), and this
had a cubic box with dimensions of 30 Å. For each ginsenoside the
resulting poses were clustered by heavy atom root-mean-square
deviation using the average-linkage method, and a representative
structure was chosen from themodel closest to the centroid of themost
populated cluster. For ginsenoside-F1 and 20(S)-Rg3 the most popu-
lated cluster made up 31% and 62% of all solutions, respectively.
Data and Statistical Analysis. Results are expressed as means
6 S.D. from the indicated number of experiments. For YO-PRO-1 dye
uptake and intracellular calcium experiments, each independent
experiment used triplicate wells, and the means of the replicates
were collated and plotted. Technical replicates were used to ensure
reliability of fluorescence values. Cell viability data were normalized
to the vehicle control for each experiment after background correction
had been performed. Dose-response curveswere plotted by a nonlinear
regression fit with variable slope using GraphPad Prism software
version 7. Half-maximal responses are expressed as EC50 values with
95% confidence intervals. These values were calculated from the
collated data for each compound from three independent experiments.
Statistical differences were determined by analysis of the data by one-
way ANOVA followed by Dunnett’s multiple comparison test or
Sidak’s multiple comparison test using GraphPad Prism version 7.
P , 0.05 was the accepted minimum level of significance.
Results
To measure positive modulator activity at human P2X7
receptors, we used a well characterized HEK-hP2X7 stable
cell line (Helliwell et al., 2015) and a YO-PRO-1 dye uptake
assay performed on a Flexstation 3 plate reader. Figure 1A
shows a typical dye uptake response to an approximate EC50
concentration of agonist (200 mM ATP) and the effect of
coadministration of ginsenoside-CK or ginsenoside-Rd at
a final concentration of 10 mM. We previously demonstrated
that pretreatment with a selective P2X7 antagonist
AZ10606120 abolished the response, confirming that the effect
of the ginsenosides was dependent on P2X7 activation
(Helliwell et al., 2015). Dose-response experiments demon-
strated that ginsenoside-CK and ginsenoside-Rd have two
effects on ATP-induced responses at hP2X7 (Fig. 1B): an
increase in the maximum response (a type I PAM effect) and
Fig. 1. Positive allosteric effects of protopanaxadiol ginsenosides on P2X7. (A) A YO-PRO-1 iodide uptake assay was used to determine the effect of
multiple ginsenosides on human P2X7 stably expressed in HEK-293 cells. Agonist (ATP, 200 mM) and modulator (10 mM) or vehicle (veh) were premixed
at 10 final concentration and auto-injected together (coinjection) using a Flexstation 3 multimode plate reader. YO-PRO-1 dye uptake (relative
fluorescence units (RFU)) was measured over 300 seconds. Data are expressed as area under curve means6 S.D. (B) Dose-response curves to ATP in the
absence and presence of 10 mM ginsenoside-CK, -Rd, or -Rb1 or the aglycone PPD with a four-parameter nonlinear regression. Data are collated from
three independent experiments each performed in triplicate. Error bars represent S.D. (C) Chemical structures for each of the ginsenoside positive
modulators and the inactive aglycone PPD are shown.












a shift in the dose-response curve to the left (a type II PAM
effect), thereby enhancing the maximum effect of the agonist
and reducing the EC50 value respectively. Classification of
type I, type II and type I/II mixed PAM effects have been
previously used for N-methyl-D-aspartate (NMDA) receptors
(Hackos and Hanson, 2017), and the same naming convention
for P2X receptors is discussed in a recent review (Stokes et al.,
2020). Ginsenoside-CK reduced the EC50 for ATP to 61.6 mM
compared with an average EC50 for ATP + vehicle (DMSO) of
219 mM (n = 5 experiments) and increased the maximum
response by 2.4–4.4-fold (Table 1). Both ginsenoside-CK and
ginsenoside-Rd have mixed type I/II effects. Ginsenoside-Rb1
increased the maximum response by 1.9-fold but had little
effect on the EC50 value (175.9 mM; Fig. 1B) and therefore has
only type I PAM activity. The aglycone ginsenosidemetabolite
PPD had no effect on the ATP dose-response curve (Fig. 1B).
Investigating Glycosylation Patterns. We assumed
that the carbohydrate groups play a key role in mediating
Fig. 2. Screening glycosides containing disaccharide and trisaccharide moieties at P2X7. (A) Initial experiments used a fixed concentration of ATP (200
mM final) and glycoside (10 mM final) to screen selected glycosides at P2X7. Data are collated from two to four independent experiments. Ginsenoside-CK
was used as the control PAM and is shown in blue. YO-PRO-1 uptake was measured as area under curve (50–300 seconds), and data are expressed as
percentage of control, where the control is ATP +DMSO. One-way ANOVAwith Dunnett’smultiple comparisons test was performed. *P, 0.05 compared
with DMSO control. (B) Dose-response curve to ATP in the presence of vehicle (DMSO), ginsenoside-CK, or gypenoside XVII (10 mM). (C) Dose-response
curve to ATP in the presence of vehicle (DMSO), ginsenoside-CK, or gypenoside XLIX (10 mM). (D) Dose-response curve to ATP in the presence of vehicle
(DMSO), ginsenoside-CK, or saikosaponin A (10 mM). Data points are means 6 S.D. The same curves from DMSO and ginsenoside-CK are shown in (B
and D). (E) Summary of data from YO-PRO-1 uptake experiments in HEK-hP2X7 cells or parental nontransfected HEK-293 cells in response to drug
alone (saikosaponin A or solanine). (F) Lack of effect of the P2X7-selective antagonist AZ10606120 (AZ106; 10 mM) on ATP-induced YO-PRO-1 uptake
when solanine or saikosaponin were used. One-way ANOVAwith Sidak’smultiple comparisons test was performed. *P, 0.05, ns denotes not significant.





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































this response at P2X7 since the aglycone PPD had no effect
(Fig. 1B). Our previous study identified a binding site within
the human P2X7 trimeric structure based on computational
docking to a homology model. The single glucose moiety on
ginsenoside-CK makes predicted interactions with P2X7 b-
strands lining the lateral portals which connect the agonist-
binding site to the ion channel transmembrane domains
(Bidula et al., 2019b). We investigated the effect of varying
the number of sugar moieties attached to the steroid-like
scaffold by searching for chemicals similar to ginsenosides
that were commercially available as purified chemicals. We
excluded ginsenosides from the protopanaxatriol series with
sugars attached on C-6 as our previous work has demon-
strated these compounds to have no activity at P2X7
(Helliwell et al., 2015). We identified a number of candidate
glycosides to test (Table 1) and screened these compounds at
a final concentration of 10 mM on hP2X7 responses using
a fixed concentration of ATP (200 mM) in the YO-PRO-1 dye
uptake assay. Focusing on glycosides containing a disaccha-
ridemoiety first (Fig. 2) we found that ginsenoside-Rg3 (mixed
isomers) and gypenoside XLIX showed a small increase in the
ATP-induced YO-PRO-1 response, which was not statistically
significant (Fig. 2A), whereas saikosaponin A and solanine
both showed a large increase in the ATP-induced YO-PRO-1
dye uptake response (Fig. 2A). Most other glycosides in this
category showed no modulation of P2X7 (esculentoside A,
mogroside V, glycyrrhizic acid, and stevioside). Stevenleaf
showed a minor modulation increasing the maximum re-
sponse only (1.64-fold; Supplemental Fig. 1). Dose-response
experiments demonstrated that gypenoside XVII has a type II
PAM activity at P2X7 (Fig. 2B), reducing the EC50 value for
ATP (Table 1) and increasing the maximum response by 2-
fold. In contrast, gypenoside XLIX did not reduce the EC50
value for ATP (Table 1) but did increase the maximum
response by 1.9-fold (Fig. 2C). Further investigations into
saikosaponin A (Fig. 2D) revealed that this glycoside
Fig. 3. Screening glycosides containing monosaccharide moieties at P2X7. Dose-response curves to ATP in the presence of vehicle (DMSO), ginsenoside-
CK, and the following: daucosterol (10 mM) (A), stevioside (SV; 10 mM) (B), ginsenoside-F1 (F1; 10 mM) (C), ginsenoside-F2 (F2; 10 mM) (D), ouabain (10
mM) (E), or scilliroside (10 mM) (F). Ginsenoside-CK is demonstrated throughout as the reference compound (same data shown in each plot). Data are
collated from three independent experiments each performed in triplicate. Error bars represent S.D.












increased YO-PRO-1 uptake at all concentrations of ATP
tested and could induce YO-PRO-1 uptake in nontransfected
HEK-293 cells (which have no expression of P2X7) and in
HEK-hP2X7 cells in the absence of ATP (Fig. 2E), suggesting
that this effect was not P2X7-dependent. We confirmed this by
pretreating HEK-hP2X7 cells with a P2X7-selective antago-
nist, AZ10606120. ATP-induced responses were abolished in
cells treated with 10 mM AZ10606120, as were responses
induced by ATP + ginsenoside-CK (Fig. 2F). However,
responses to ATP + saikosaponin A or ATP + solanine were
unaffected by AZ10606120 pretreatment, suggesting that
P2X7 was not involved (Fig. 2F).
We then investigated glycosideswithmonosaccharide attach-
ments including daucosterol, ginsenoside-F2, ginsenoside-F1,
ouabain, and scilliroside (Table 1). Dose-response experi-
ments demonstrated that ginsenoside-F2 could both increase
the maximum response and reduce the EC50 value for ATP
(Table 1) and displayed a similar mixed type I/II effect as
ginsenoside-CK (Fig. 3D). Ouabain, daucosterol, and scilliro-
side had no effect on the ATP dose-response curves (Fig. 3).
Interestingly, ginsenoside-F1, which has an almost identical
chemical structure to ginsenoside-CK, did not potentiate
P2X7 responses (Fig. 3C). The presence of one additional
hydroxyl group on C-6 is the only difference between
ginsenoside-CK and ginsenoside-F1, and this could poten-
tially interfere with correct positioning into the P2X7 binding
pocket.
Computational Docking. To investigate the predicted
theoretical docking differences between ginsenoside-CK and
ginsenoside-F1, we used computational docking to a homology
model of human P2X7 (Bidula et al., 2019b). Replacing
ginsenoside-CK (Fig. 4A) in the open ATP-bound model of
hP2X7 with ginsenoside-F1 resulted in an analogous pre-
dicted pose (Fig. 4B) and this would orient the additional
hydroxyl group on C-6 to be facing the hydrophobic side of the
pocket close to L320 and F322. Since ginsenoside-F1 has no
activity at P2X7, this purely theoretical pose suggests that
steric hindrance and a repulsive effect would prevent
ginsenoside-F1 from interacting with the PAM site at P2X7.
Furthermore, there would likely be an energy penalty due to
poor solvation of the additional OH group within the hydro-
phobic pocket.
Concurrently we investigated chemicals thought to bind in
an inverted mode such as ginsenoside-Rd (Bidula et al.,
2019b). Ginsenosides with sugars attached to C-3 rather than
C-20 are predicted to insert sugars deep into the pocket and
would have the C-20 side chain solvent-exposed. We have
previously demonstrated that themonosaccharide ginsenoside-
Rh2 is able to potentiate hP2X7 responses (Helliwell et al.,
2015) and have proposed a predicted binding model (Bidula
et al., 2019b). Ginsenoside-Rh2 and ginsenoside-Rg3 are also
predicted to bind in this inverted mode, and both of these
ginsenosides can exist as two diasteromers with regard to the
C-20 side chain. The natural product form in P. ginseng is
believed to be the 20(S)-diastereomer (Qi et al., 2011; Yang
et al., 2014), and this is thought to have higher bioactivity
than the 20(R)-diastereomer (Wei et al., 2012). We investi-
gated the individual pure diastereomers to determine if this
had any bearing on PAM activity at P2X7 and found that only
the 20(S)-diastereomers of Rg3 and Rh2 are active as PAMs
at hP2X7 (Fig. 5). This suggests that the stereospecific
positioning of the –OH group on C-20 may be critical for
mediating the potentiating effect. To investigate which part
of P2X7 would be closest to C-20, we used computational
induced-fit docking using Glide as previously reported
(Bidula et al., 2019b). The most populated pose for 20(S)-
Rg3 is presented in Fig. 6, and this places the C-20 hydroxyl
group pointing away from the hydrophobic side of the pocket.
In an analogous theoretical pose, 20(R)-Rg3 would have this
C-20 hydroxyl group in close proximity to the hydrophobic
face, increasing steric hindrance and repulsive effects plus
the desolvation penalty as mentioned above, preventing
20(R)-Rg3 and 20(R)-Rh2 from interacting with the binding
pocket on P2X7.
Modulation of Endogenous Human P2X7 in Immune
Cells. Finally, we verified our findings on the identified
active versus inactive glycosides by using a human THP-1
monocytic cell line known to endogenously express P2X7
(Fig. 7). Using fura-2 AM loaded cells, we measured ATP-
induced calcium responses (Fig. 7A) and found that there was
a rapid peak increase in calcium followed by a sustained
elevation of calcium over 300 seconds of recording. Pretreat-
ment of THP-1 cells with commercially available P2X7-
selective antagonists such as AZ11645373 or AZ10606120
did not dramatically affect the response to 500 mM ATP
(Fig. 7), but coapplication of ginsenoside-CK with 500 mM
ATP increased the peak response and the sustained elevation
in [Ca2+]i (Fig. 7). This increased response could be completely
Fig. 4. Molecular docking of ginsenoside-
CK and ginsenoside-F1 to the central
vestibule pocket of hP2X7. Ginsenoside-
CK (cyan) docked into the central vesti-
bule in the ATP-bound homology model of
human P2X7 and right, ginsenoside-F1
(green) docked into the same site. Side
chains of amino acid residues of hP2X7
implicated in interactions are shown.












abolished in cells pretreated with either AZ11645373 (10 mM)
or AZ10606120 (10 mM), suggesting that the ginsenoside-CK
potentiated response is solely mediated by P2X7 with no
involvement of other purinergic receptors. Using the same
protocol we investigated whether we could verify active and
inactive glycosides as PAMs and confirmed that ginsenoside-
F2, ginsenoside-Rd, and ginsenoside-20(S)-Rg3 all potenti-
ated the ATP-induced calcium response in THP-1 cells and
that this potentiation was abolished by pretreatment with
a P2X7-selective antagonist (Fig. 7C).
Fig. 5. Diastereoisomers of ginsenosides
have different activity at hP2X7. (A) Dose-
response curves to ATP in the presence
of vehicle (DMSO), 20(S)-ginsenoside-
Rg3, or 20(R)-ginsenoside-Rg3 (10 mM).
(B) Dose-response curves to ATP in the
presence of vehicle (DMSO), ginsenoside-
20(S)-Rh2, or ginsenoside-20(R)-Rh2 (10
mM). Data are collated from three inde-
pendent experiments and are means 6
S.D. The same DMSO data are shown in
both plots. (C) Chemical structures of
ginsenoside-Rg3 and ginsenoside-Rh2
are shown with the stereo-centers high-
lighted in red.
Fig. 6. Induced-fit docking of 20S-Rg3 at human
P2X7 ginsenoside-20(S)-Rg3 (green) docked into
the central vestibule site in a homology model of
ATP-bound human P2X7 (open state). The pre-
dicted orientation of the stereocentre C-20 is such
that the –OH is pointing away from the hydro-
phobic face of the binding site, thus minimizing
any repulsive interactions. Key side chains of
residues D318, L320, and F322 are indicated.












We then determined if the identified active PAMs ginsenoside-
F2, 20(S)-Rg3, and gypenoside XVII could enhance P2X7-
dependent cell death in thehighly expressingHEK-hP2X7model
using ginsenoside-CK as a positive control. Both ginsenoside-F2
and 20(S)-Rg3 could reduce cell viability over 24 hours when
applied in combination with ATP, and this was prevented by
pretreatment with AZ10606120 (Fig. 7D). However, neither
gypenoside XVII nor 20(R)-Rg3 in combination with ATP
Fig. 7. The PAM effects of glycosides in human THP-1monocyte cell line. (A) ATP-induced calcium responses weremeasured in fura-2 AM loaded THP-1
cells in suspension using a Flexstation 3 plate reader. Agonist (500 mM ATP) and PAM (ginsenoside-CK 10 mM) were coinjected after establishment of
a baseline for 40 seconds. Cells were preincubatedwith various P2X7 antagonists for 10minutes prior to start of plate recordings. (B) Summary of collated
data from calcium measurements. Fura-2 responses were calculated as area under curve. Data were analyzed using one-way ANOVA with Tukey’s
multiple comparisons test to assess the effect of antagonists. *P , 0.05. (C) Investigating the P2X7 dependence of glycoside effects on ATP-induced
calcium responses. AZ10606120 (AZ106; 10 mM) was added to cells to block P2X7 receptors prior to measuring calcium responses. Data were analyzed
using one-way ANOVA with Dunnett’s multiple comparison test comparing each column against the control (500 mMATP + DMSO). *P, 0.05. (D) Cell
viability experiments were performed over 24 hours using HEK-hP2X7 cell line. Alamar blue fluorescence was measured, and data were normalized to
percentage of control (DMSO). Data were collated from five independent experiments. One-way ANOVA was used to analyze the data with Sidak’s
multiple comparisons test to compare selected pairs of columns (DMSO + ATP vs. ginsenoside + ATP). *P , 0.05. (E) Cell viability experiments were
performed over 24 hours using THP-1 cells. Alamar blue fluorescence was measured and data were normalized to percentage of control (DMSO). Data
were collated from five independent experiments. One-way ANOVA was used to analyze the data with Sidak’s multiple comparisons test to compare
selected pairs of columns (DMSO + ATP vs. ginsenoside + ATP). *P , 0.05.












affected cell viability (Fig. 7D). In THP-1 cells, treatment with
500 mM ATP significantly reduced cell viability to 73.3% 6
14.4% of control (Fig. 7E), although this may not be P2X7-
dependent due to the lack of effect of AZ10606120. Only
ginsenoside-CK could significantly enhance this ATP-induced
cell death in THP-1 cells (Fig. 7E).
Discussion
In summary, we have demonstrated that the chemical
requirements for positive allosteric modulators at P2X7
appear to be quite stringent. Dose-response experiments
demonstrate that ginsenoside-CK and ginsenoside-Rd have
two effects on ATP-induced responses at hP2X7 (Fig. 1B): an
increase in the maximum response (a type I PAM effect) and
a shift in the dose-response curve to the left (a type II PAM
effect), thereby enhancing the maximum effect of the agonist
and reducing the EC50 value. Our previous work has shown
ginsenoside-CK, a triterpenoid glycoside with one glucose
attachment, to have the best PAM effect at human P2X7.
Here we show that ginsenoside-F2 and ginsenoside-20(S)-Rg3
have equivalent PAM activity at P2X7. We investigated
a range of glycosides with different numbers of carbohydrate
groups attached, and alternative sugar groups to glucose. Of
these, gypenoside XVII showed the best PAMactivity at P2X7.
This glycoside is a dammarene glycoside found in Panax
species, typically Panax notoginseng (Sakah et al., 2013).
Gypenoside XVII has a single glucose attached at C-3 and
two glucose groups attached at C-20 [a b-D-glucopyranosyl-
(1–6)-b-D-glucopyranoside]. It is very similar in structure to
stevenleaf (also known as gypenoside IX; Table 1), but the
sugar attachments on C-20 are different. Stevenleaf has
a glucose-xylose disaccharide attached at C-20, whereas in
gypenoside XVII, this is a glucose-glucose disaccharide. The
reduced activity of stevenleaf (Supplemental Fig. 1) compared
with gypenoside XVII suggests that there is a preferential
requirement for glucose within the binding pocket on P2X7.
Similarly, esculentoside A has a similar structure to ginseno-
side-20(S)-Rg3 with a disaccharide on C-3, although this is
composed of glucose-xylose, whereas Rg3 has a glucose-
glucose disaccharide. Esculentoside A was inactive at P2X7
(Supplemental Fig. 1).
Most useful in terms of defining a structure-activity re-
lationship for PAMs at P2X7 was the finding that modifica-
tions at C-6 were not tolerated. Ginsenoside-F1 showed no
PAM activity at P2X7, and computational docking suggests
that this additional hydroxyl onC-6 faces the hydrophobic side
of the predicted binding pocket. This may be incompatible
with binding to P2X7 to produce effective potentiation of
responses. We have not performed a binding assay to de-
termine if this lack of activity equates to a lack of binding to
P2X7 rather than equivalent binding and a lack of effect.
Currently there are no suitably labeled ginsenosides available
as probes, and this is something we shall explore in future
studies. We also discovered that the stereochemistry of 20(S)
versus 20(R) in ginsenoside-Rg3 and ginsenoside-Rh2 have
a clear effect on PAM activity with only the 20(S) diaster-
eomers retaining good PAM activity. Again, computational
docking suggests this C-20 hydroxyl group to be close to the
highly hydrophobic side of the predicted binding pocket, and
we hypothesize that this is important in correct positioning
leading to effective potentiation of ATP-dependent responses.
Regarding the differences in the terpenoid backbone, several
of the compounds we selected for testing contained carbohy-
drate at either end of the molecule but did not contain the
dammarene scaffold. For example, daucosterol is a monosac-
charide (glucose) but contains a sitosterol-like scaffold. This
includes a double bond that changes the shape of the scaffold
and this has a detrimental effect on activity at P2X7. The
key elements to the structure-activity relationship for glyco-
sides at P2X7 are summarized in Fig. 8 showing two
predicted binding modes for glycosides. Figure 8A shows
the ginsenoside-CK binding mode with C-20 glucose inserted
into the binding pocket. Figure 8B shows the inverted mode
for ginsenosides with C-3 glucose inserted into the binding
pocket. Substitutions are tolerated on C-3 and C-20, but
glucose is the preferred sugar attachment. Monosaccharides
have higher activity than most disaccharides, and no sub-
stitution is tolerated at C-6 (Fig. 8A). In the inverted mode,
the stereochemistry of the hydroxyl group on C-20 is critical
for activity (Fig. 8B). In both cases the dammarene scaffold is
favored over a sitosterol scaffold.
It is important to perform full dose-response analysis to
determine those compounds that have PAM effects at P2X7.
Saikosaponin A and solanine could increase the ATP-induced
dye uptake in the screen on HEK-hP2X7 cells (Fig. 2A), but
further investigation showed that these compounds had a toxic
effect on the cells, inducing YO-PRO-1 dye uptake in the
absence of ATP or the absence of the P2X7 receptor (Fig. 2).
Saikosaponins have been linked to multiple biologic effects
including induction of apoptosis (Li et al., 2018).
Several groups have demonstrated endogenous steroidal
compounds to have positive allosteric modulator activity at
P2X receptors. Dehydroepiandrosterone and progesterone can
potentiate rodent P2X2 receptors (De Roo et al., 2003, 2010),
and 17b-ester derivatives of testosterone also potentiate rat
P2X2 and P2X4 (Sivcev et al., 2019). None of these compounds
had activity at P2X7 receptors. Lithocholic acid, a bile acid,
has potentiating activity at P2X7 and P2X4 (rat) but inhibits
rat P2X2 (Sivcev et al., 2020). This suggests there may exist
endogenous regulators of P2X channel activity. It has been
suggested that the bile acids may share a similar binding site
to ivermectin, close to transmembrane domain 1 (Sivcev et al.,
2020).
Positive allosteric modulation of P2X7 may be important in
a number of contexts (Stokes et al., 2020). In this study we
used the human monocytic cell line, THP-1, which has been
used in other studies to investigate human P2X7 responses
(Stokes et al., 2006; Gadeock et al., 2010). Native P2X7
responses are small in this cell line, likely masked by the
multitude of other purinergic ATP-responsive receptors pres-
ent. P2X7-selective antagonists did not affect the ATP-
induced calcium responses dramatically (Fig. 7A), yet we did
see robust potentiation of the ATP-induced calcium response
that was mediated by P2X7. The THP-1 cell line carries a loss-
of-function polymorphism in the C-terminus of P2X7,
rs3751143, encoding the Glu496 . Ala amino acid substitu-
tion. Sequencing of exon 13 reveals heterozygosity for
rs3751143 (Supplemental Fig. 2), confirming the work in
Gadeock et al. (2012). Our data clearly show that P2X7
responses in THP-1 cells can be enhanced by ginsenoside-
CK, and we can effectively rescue deficient P2X7 receptor
responses in humans carrying this loss-of-function polymor-
phism. Ginsenoside-F2 and ginsenoside-Rd were also effective












at increasing P2X7 responses in THP-1 cells (Fig. 7), and
ginsenoside-F1 was inactive. Extending this set of data that
measures immediate P2X7 responses, we looked at P2X7-
mediated cell death first in HEK-hP2X7 cells using an Alamar
blue cell viability assay. Ginsenoside-CK, ginsenoside-Rd,
20(S)-Rg3, and ginsenoside-F2 were very effective at enhanc-
ing cell death in combination with ATP; however, gypenoside
XVII was unable to enhance P2X7-mediated cell death in this
cell line (Fig. 7D). At this stage, it is unclear why this would be
the case. Future investigations into the longevity of the
potentiation may reveal that gypenoside XVII has a shorter
duration of action than the ginsenosides, perhaps due to
differential binding modes. Repeating this work in THP-1
cells showed that only ginsenoside-CK was effective at
potentiation of cell death induced by ATP (Fig. 7E). This
may be due to the lower level of expression of P2X7 in THP-1
cells, the expression of other purinergic receptors that may
bind ginsenosides such as P2X4, or simply due to duration of
action. It is also conceivable that monocytes may release
factors such as glycosidase enzymes that can degrade
ginsenosides.
Other compounds can act as positive allosteric modulators
of P2X7 (Stokes et al., 2020), including clemastine (Nörenberg
et al., 2011), tenidap (Sanz et al., 1998), ivermectin (Nörenberg
et al., 2012), and polymyxin B (Ferrari et al., 2004). These bear
no structural similarities to ginsenosides, although ivermec-
tin is a glycoside, containing two oleandrose sugars. As yet
nothing is known about the potential site of action of
ivermectin on P2X7, although on P2X4 the binding site is
proposed to be close to transmembrane domain 1 (Asatryan
et al., 2010, Samways et al., 2012). In terms of therapeutic
relevance of PAMs acting at P2X7, most exciting is the
potential to enhance the microbicidal activity of immune cells.
P2X7 has been implicated in regulation of pathogen killing,
particularly those residing in intracellular locations such as
mycobacteria and parasites (Di Virgilio et al., 2017, Savio
et al., 2018). The mechanisms by which P2X7 contributes to
reduction of pathogen burden are not yet well understood but
could involve cytokine/mediator secretion, reactive oxygen
species generation, or host cell apoptosis. We recently showed
that potentiation of P2X7 responses with ginsenoside-CK
changed the type of cell death in the J774 macrophage cell
line compared with high concentrations of ATP (Bidula et al.,
2019a), and this could be relevant within an immune re-
sponse. In models of infection, most of the work has been
performed on P2X7-deficient mice to understand the role of
this receptor within the host immune response. However,
there has not been an in vivo study to investigate pharmaco-
logical targeting of P2X7 with a PAM. This idea has been
tested in a zebrafish whole-animal study for Mycobacterium
marinum infection using clemastine to potentiate P2X7
(Matty et al., 2019), providing evidence that targeting P2X7
may be beneficial to control mycobacterial infections.
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